Compare BCYC & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCYC | VALU |
|---|---|---|
| Founded | 2009 | 1931 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 353.1M |
| IPO Year | 2019 | 1995 |
| Metric | BCYC | VALU |
|---|---|---|
| Price | $5.04 | $35.30 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 562.4K | 1.1K |
| Earning Date | 04-30-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 3.68% |
| EPS Growth | N/A | ★ 8.91 |
| EPS | N/A | ★ 1.92 |
| Revenue | N/A | ★ $36,257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.39 |
| Revenue Growth | N/A | ★ 1.08 |
| 52 Week Low | $4.24 | $33.67 |
| 52 Week High | $9.55 | $41.85 |
| Indicator | BCYC | VALU |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 42.05 |
| Support Level | $5.03 | $35.15 |
| Resistance Level | $7.14 | $38.30 |
| Average True Range (ATR) | 0.31 | 0.64 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 77.14 | 43.93 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.